Trial reportOral and maxillofacial surgery2026
Do successive intra-articular injections of tenoxicam or meloxicam affect the treatment outcomes of temporomandibular joint anterior disc displacement with reduction? (a randomized controlled trial).
Trial report in Oral and maxillofacial surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06403046 (Does Successive Intra-articular Injections of Tenoxicam or Meloxicam Affect Treatment Outcomes of Temporomandibular Joint Anterior Disc Displacement With Reduction?), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Does Successive Intra-articular Injections of Tenoxicam or Meloxicam Affect Treatment Outcomes of Temporomandibular Joint Anterior Disc Displacement With Reduction? (A Randomized Controlled Trial)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe study compares the effect of repeated intra-articular injection of Tenoxicam versus Meloxicam after arthrocentesis on modulating the symptoms of TMJ anterior disc displacement with reduction (ADDWR).
methodsThirty patients were recruited for this randomized controlled trial. They were randomly and equally allocated to two groups. After arthrocentesis, patients received three injections at one-month intervals with either Tenoxicam (Tx group) or Meloxicam (Mx group), while Visual Analogue Scale (VAS), maximal interincisal opening (MIO), and TMJ clicking were measured preoperatively and at one, three, six, and nine months postoperatively.
resultsWhile both groups showed significant improvements in pain and increased MIO, the improvement in the Tx group was significantly greater than that in the Mx group. After symptom alleviation during the one- to three-month interval, pain gradually increased from the third month onward in both groups. At the same time, MIO began to decrease from the sixth month in the Mx group and the ninth month in the Tx group. The correlations between pain reduction and both MIO and clicking in the Tx group were statistically significant (p < 0.001*) & (p = 0.004*), respectively, compared to statistically insignificant correlations among the Mx group (p = 0.295) & (p = 0.266). Nevertheless, both groups showed no significant improvement in the clicking bypass.
conclusionThe successive injections of both Tenoxicam and Meloxicam after arthrocentesis were effective; while Tenoxicam offered superior statistical pain reduction and enhanced mouth opening, the substantial clinical benefit (SCB) of both drug injections was equivalent.
trial registrationThe study was registered on www.clinicaltrials.gov (#: NCT06403046) on May 7, 2024.
Indexed as
Identifiers
41957190What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.